[CLSTR]
< Back to situations

[ORGANIZATION]

Moderna

Featured in 53 tracked stories · first seen

Situations

[ACTIVE] [BUSINESS] [US] [DE] [TR]

Solana sees surging activity, RWA growth, and legal relief

27 clusters · 96 sources · last updated

Latest: Solana sees rising activity in tokenized stocks and prediction markets

Solana continues to experience significant network growth and market recovery, marked by record-high token issuance and legal developments. The network recently reached a peak of 263,000 tokens issued in a single day, la

[ACTIVE] [BUSINESS] [CH] [DE]

Biotechnology sector market performance

3 clusters · 8 sources · last updated

Latest: Biotech stocks reach 52-week highs amid clinical updates and portfolio shifts

The biotechnology sector has experienced significant volatility and growth driven by clinical trial developments and financial reporting. In late August 2026, the market showed contrasting trends. BioNTech shares fell 8

[ACTIVE] [HEALTH] [CD] [UG] [US]

DRC Ebola outbreak expands and impacts healthcare workers

406 clusters · 3144 sources · last updated

Latest: Ebola outbreak in DRC shows mixed progress as cases surge in North Kivu

The Bundibugyo-strain Ebola outbreak in the Democratic Republic of Congo (DRC) continues to escalate, marking the fastest-growing and deadliest epidemic in the country’s history. As of mid-September 2026, confirmed cases

[ACTIVE] [HEALTH] [US] [AR] [GR]

Respiratory virus vaccination guidance and developments

8 clusters · 26 sources · last updated

Latest: US health officials urge vaccination against seasonal respiratory viruses

Health experts and medical organizations continue to emphasize the importance of vaccination as the respiratory virus season approaches. Initial reports highlighted the impact of the 2024-25 U.S. flu season, which result

[ACTIVE] [HEALTH] [TW] [HK]

Taiwan faces rising influenza and enterovirus outbreaks

14 clusters · 19 sources · last updated

Latest: Taiwan health officials warn of rising influenza and enterovirus outbreaks

Taiwan continues to face a complex infectious disease landscape as influenza and enterovirus outbreaks rise simultaneously. Between September 8 and September 14, influenza outpatient visits increased by 16.5% in a single

[ACTIVE] [HEALTH] [IT] [US]

Advancements in cancer immunotherapy and vaccines

2 clusters · 4 sources · last updated

Latest: Cancer vaccine progress faces threat from disinformation

Advancements in cancer immunotherapy have focused on two primary areas: the development of lab-grown T-cells from hematopoietic stem cells and the use of personalized mRNA vaccines. The stem cell platform aims to provide

[ACTIVE] [HEALTH] [US] [ES]

Moderna and Merck melanoma vaccine clinical trials

9 clusters · 443 sources · last updated

Latest: Moderna reports positive Phase III results for personalized cancer vaccine

Moderna and Merck (MSD) have reported positive Phase 3 clinical trial results for intismeran autogene (also known as V940 or mRNA-4157), an experimental personalized mRNA cancer vaccine. The therapy is designed to target

[ACTIVE] [HEALTH] [US] [BR] [DE]

Cancer immunotherapy research and access challenges

3 clusters · 10 sources · last updated

Latest: Cancer therapy advances face significant access challenges

Recent research into cancer immunotherapy has focused on understanding side effects, treatment timing, and the influence of other vaccines on patient outcomes. Initial studies identified that inflammatory arthritis caus

[ACTIVE] [HEALTH] [PL]

Poland COVID-19 vaccination guidelines 2026/2027

3 clusters · 12 sources · last updated

Latest: Poland launches 2026/2027 COVID-19 vaccination campaign

The Polish Ministry of Health has established guidelines and initiated the 2026/2027 COVID-19 vaccination campaign. The program provides free vaccinations for eligible individuals, with the state budget funding procureme

[QUIET] [BUSINESS]

Analyst rating shifts in energy and biotech sectors

3 clusters · 3 sources · last updated

Latest: Fluence Energy downgraded as healthcare stocks hit milestones

Market analysts have issued various rating adjustments and price target shifts across the energy and biotechnology sectors. In the energy sector, Fluence Energy has faced significant downward pressure. Following a downg

[QUIET] [BUSINESS] [US] [JP] [BR]

SanDisk AI rally continues amid index inclusion and AI risks

38 clusters · 81 sources · last updated

Latest: SanDisk shares surge following S&P 100 index inclusion announcement

SanDisk’s AI-driven rally has seen its stock rise over 3,900% in twelve months, exceeding $1,550. Driven by demand for NAND technology in AI infrastructure, the company reported fiscal Q4 2026 revenue of $8.965 billion—a

[QUIET] [HEALTH] [US]

US FDA COVID-19 vaccine updates

3 clusters · 27 sources · last updated

Latest: COVID-19 cases rise across 47 U.S. states

The U.S. Food and Drug Administration (FDA) has approved updated COVID-19 vaccines for the 2026-2027 season to target the XFG subvariant of the JN.1 coronavirus lineage. The approved vaccines include mRNA formulations fr

[QUIET] [HEALTH] [CA] [NO]

Advancements in RNA therapeutic technologies

3 clusters · 15 sources · last updated

Latest: RNA research advances potential treatments for genetic diseases

Developments in RNA technology are expanding from messenger RNA (mRNA) applications toward new therapeutic frontiers, including transfer RNA (tRNA). In oncology, personalized mRNA cancer vaccines are being tested in co

[QUIET] [HEALTH] [CD] [CA] [GB]

Bundibugyo Ebola vaccine trials

4 clusters · 58 sources · last updated

Latest: Minapharm Group receives $16.5M for Bundibugyo ebola vaccine

Clinical efforts to address the Bundibugyo Ebola outbreak in the Democratic Republic of the Congo (DRC) continue to expand. The outbreak, which has seen infections surpass 4,000 cases, has prompted the WHO and Africa CDC

[QUIET] [HEALTH] [US] [HK]

FDA approval of Moderna mRNA influenza vaccine

3 clusters · 6 sources · last updated

Latest: FDA approves first mRNA influenza vaccine as regional vaccination efforts expand

The U.S. Food and Drug Administration (FDA) has approved Moderna’s mFLUSIVA, the first mRNA-powered influenza vaccine. This technology utilizes a genetic blueprint to produce viral proteins, offering a faster production

[QUIET] [HEALTH] [US]

Moderna mRNA flu vaccine US approval

4 clusters · 68 sources · last updated

Latest: Moderna's mFLUSIVA receives FDA approval as first mRNA flu vaccine

In early August 2026, the U.S. Food and Drug Administration (FDA) authorized Moderna’s mRNA-based seasonal influenza vaccine, mFlusiva. On 6 August, the agency granted full approval for adults aged 50–64, based on a late

[QUIET] [BUSINESS] [US]

Tempus AI earnings, Personalis acquisition, and market shift

5 clusters · 9 sources · last updated

Latest: Tempus AI shares surge following Merck and Moderna cancer vaccine trial results

In early August 2026, Tempus AI reported a 22% year-over-year increase in second-quarter revenue to $382.5 million, driven by growth in both diagnostics and data-applications segments. The company announced FDA approval

Also covered in